Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT

Research output: Contribution to journal › Journal article › Research

Standard

Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. / Ziebell, Morten; Thomsen, Gerda; Knudsen, Gitte M; de Nijs, Robin; Svarer, Claus; Wagner, Aase; Pinborg, Lars H.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, No. 1, 01.01.2007, p. 101-9.

Research output: Contribution to journal › Journal article › Research

Harvard

Ziebell, M, Thomsen, G, Knudsen, GM, de Nijs, R, Svarer, C, Wagner, A & Pinborg, LH 2007, 'Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT', European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 1, pp. 101-9. https://doi.org/10.1007/s00259-006-0161-z

APA

Ziebell, M., Thomsen, G., Knudsen, G. M., de Nijs, R., Svarer, C., Wagner, A., & Pinborg, L. H. (2007). Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 34(1), 101-9. https://doi.org/10.1007/s00259-006-0161-z

Vancouver

Ziebell M, Thomsen G, Knudsen GM, de Nijs R, Svarer C, Wagner A et al. Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. European Journal of Nuclear Medicine and Molecular Imaging. 2007 Jan 1;34(1):101-9. https://doi.org/10.1007/s00259-006-0161-z

Author

Ziebell, Morten ; Thomsen, Gerda ; Knudsen, Gitte M ; de Nijs, Robin ; Svarer, Claus ; Wagner, Aase ; Pinborg, Lars H. / Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. In: European Journal of Nuclear Medicine and Molecular Imaging. 2007 ; Vol. 34, No. 1. pp. 101-9.

Bibtex

@article{9170dfdb6dd140f3ab1916c6ed0967fa,
title = "Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT",
abstract = "The iodinated cocaine derivative [(123)I]PE2I is a new selective ligand for in vivo studies of the dopamine transporter (DAT) with SPECT. Recently, a bolus/infusion (B/I) protocol for [(123)I]PE2I measurements of DAT density was established [Pinborg LH et al. J Nucl Med 2005;46:1119-271]. The aims of this study were, firstly, to evaluate the test-retest variability using the B/I protocol and, secondly, to evaluate the B/I approach in a new group of healthy subjects using two outcome parameters, BP(1) (C(ROI)/C(plasma)) and BP(2) (C(ROI)/C(REF)).",
author = "Morten Ziebell and Gerda Thomsen and Knudsen, {Gitte M} and {de Nijs}, Robin and Claus Svarer and Aase Wagner and Pinborg, {Lars H}",
year = "2007",
month = jan,
day = "1",
doi = "http://dx.doi.org/10.1007/s00259-006-0161-z",
language = "English",
volume = "34",
pages = "101--9",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT

AU - Ziebell, Morten

AU - Thomsen, Gerda

AU - Knudsen, Gitte M

AU - de Nijs, Robin

AU - Svarer, Claus

AU - Wagner, Aase

AU - Pinborg, Lars H

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The iodinated cocaine derivative [(123)I]PE2I is a new selective ligand for in vivo studies of the dopamine transporter (DAT) with SPECT. Recently, a bolus/infusion (B/I) protocol for [(123)I]PE2I measurements of DAT density was established [Pinborg LH et al. J Nucl Med 2005;46:1119-271]. The aims of this study were, firstly, to evaluate the test-retest variability using the B/I protocol and, secondly, to evaluate the B/I approach in a new group of healthy subjects using two outcome parameters, BP(1) (C(ROI)/C(plasma)) and BP(2) (C(ROI)/C(REF)).

AB - The iodinated cocaine derivative [(123)I]PE2I is a new selective ligand for in vivo studies of the dopamine transporter (DAT) with SPECT. Recently, a bolus/infusion (B/I) protocol for [(123)I]PE2I measurements of DAT density was established [Pinborg LH et al. J Nucl Med 2005;46:1119-271]. The aims of this study were, firstly, to evaluate the test-retest variability using the B/I protocol and, secondly, to evaluate the B/I approach in a new group of healthy subjects using two outcome parameters, BP(1) (C(ROI)/C(plasma)) and BP(2) (C(ROI)/C(REF)).

U2 - http://dx.doi.org/10.1007/s00259-006-0161-z

DO - http://dx.doi.org/10.1007/s00259-006-0161-z

M3 - Journal article

VL - 34

SP - 101

EP - 109

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 1

ER -

ID: 34094258